Sensei Biotherapeutics (NASDAQ:FTH) Earns Buy Rating from Analysts at JonesTrading

JonesTrading initiated coverage on shares of Sensei Biotherapeutics (NASDAQ:FTH) in a report issued on Tuesday, MarketBeat Ratings reports. The brokerage issued a buy rating and a $55.00 price target on the stock.

Several other equities research analysts have also weighed in on the company. Robert W. Baird assumed coverage on Sensei Biotherapeutics in a report on Friday, June 26th. They issued an “outperform” rating and a $57.00 price objective for the company. Zacks Research raised shares of Sensei Biotherapeutics to a “hold” rating in a report on Tuesday, April 21st. Citizens Jmp began coverage on shares of Sensei Biotherapeutics in a report on Monday, July 20th. They set an “outperform” rating and a $51.00 price objective on the stock. Raymond James Financial started coverage on shares of Sensei Biotherapeutics in a research report on Friday, July 31st. They set an “outperform” rating and a $56.00 target price for the company. Finally, Leerink Partners started coverage on shares of Sensei Biotherapeutics in a research note on Monday, April 20th. They issued an “outperform” rating and a $50.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $54.90.

Sensei Biotherapeutics Price Performance

Shares of NASDAQ FTH opened at $24.48 on Tuesday. Sensei Biotherapeutics has a 1-year low of $7.20 and a 1-year high of $37.90. The firm has a market cap of $32.85 million, a price-to-earnings ratio of -0.17 and a beta of -0.25.

Sensei Biotherapeutics (NASDAQ:FTH) last issued its earnings results on Friday, May 15th. The company reported ($131.45) earnings per share (EPS) for the quarter. Analysts anticipate that Sensei Biotherapeutics will post -15.23 earnings per share for the current year.

Insider Activity

In related news, CFO Brian C. Stephenson acquired 9,391 shares of the company’s stock in a transaction that occurred on Wednesday, June 24th. The shares were acquired at an average price of $26.13 per share, with a total value of $245,386.83. Following the acquisition, the chief financial officer owned 26,804 shares of the company’s stock, valued at approximately $700,388.52. This trade represents a 53.93% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, major shareholder James Peyer sold 25,000 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $20.02, for a total value of $500,500.00. Following the completion of the transaction, the insider owned 130,142 shares of the company’s stock, valued at approximately $2,605,442.84. This represents a 16.11% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders purchased 49,494 shares of company stock worth $1,188,822. 7.00% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Sensei Biotherapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Vivo Capital LLC purchased a new stake in shares of Sensei Biotherapeutics in the first quarter worth about $22,758,000. Stempoint Capital LP purchased a new stake in Sensei Biotherapeutics in the 1st quarter worth approximately $4,188,000. Bank of America Corp DE boosted its holdings in Sensei Biotherapeutics by 10,692.5% in the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after purchasing an additional 32,719 shares during the period. Finally, Renaissance Technologies LLC boosted its holdings in Sensei Biotherapeutics by 178.2% in the 1st quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock valued at $1,010,000 after purchasing an additional 20,525 shares during the period. 10.50% of the stock is currently owned by institutional investors.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.